IS2331B - 2-arýlimínó-2,3-díhýdróþíasólafleiður, aðferðir til að framleiða þær og meðferðarfræðileg notkun þeirra - Google Patents

2-arýlimínó-2,3-díhýdróþíasólafleiður, aðferðir til að framleiða þær og meðferðarfræðileg notkun þeirra

Info

Publication number
IS2331B
IS2331B IS6870A IS6870A IS2331B IS 2331 B IS2331 B IS 2331B IS 6870 A IS6870 A IS 6870A IS 6870 A IS6870 A IS 6870A IS 2331 B IS2331 B IS 2331B
Authority
IS
Iceland
Prior art keywords
arylamino
preparation
methods
therapeutic use
dihydrothiazole
Prior art date
Application number
IS6870A
Other languages
English (en)
Other versions
IS6870A (is
Inventor
Moinet Christophe
Sackur Carole
Thurieau Christophe
Original Assignee
Société de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S.), Société par ActionsSimplifiée
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Société de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S.), Société par ActionsSimplifiée filed Critical Société de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S.), Société par ActionsSimplifiée
Publication of IS6870A publication Critical patent/IS6870A/is
Publication of IS2331B publication Critical patent/IS2331B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Liquid Crystal (AREA)
  • Thin Film Transistor (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
IS6870A 2001-01-12 2003-07-09 2-arýlimínó-2,3-díhýdróþíasólafleiður, aðferðir til að framleiða þær og meðferðarfræðileg notkun þeirra IS2331B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0100396A FR2819508B1 (fr) 2001-01-12 2001-01-12 Derives de 2-arylimino-2, 3-dihydorthiazoles, leurs procedes de preparation et leur utilisation therapeutiques
PCT/FR2002/000093 WO2002055510A1 (fr) 2001-01-12 2002-01-11 Derives de 2-arylimino-2,3-dihydrothiazoles, leurs procedes de preparation et leur utilisation therapeutique

Publications (2)

Publication Number Publication Date
IS6870A IS6870A (is) 2003-07-09
IS2331B true IS2331B (is) 2008-02-15

Family

ID=8858747

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6870A IS2331B (is) 2001-01-12 2003-07-09 2-arýlimínó-2,3-díhýdróþíasólafleiður, aðferðir til að framleiða þær og meðferðarfræðileg notkun þeirra

Country Status (26)

Country Link
US (1) US7220765B2 (is)
EP (1) EP1353912B1 (is)
JP (1) JP4452443B2 (is)
KR (1) KR100874298B1 (is)
CN (1) CN100534988C (is)
AR (1) AR035730A1 (is)
AT (1) ATE302765T1 (is)
AU (1) AU2002233407B2 (is)
BR (1) BR0206407A (is)
CA (1) CA2434203C (is)
CZ (1) CZ20031917A3 (is)
DE (1) DE60205717T2 (is)
DK (1) DK1353912T3 (is)
ES (1) ES2248514T3 (is)
FR (1) FR2819508B1 (is)
HU (1) HUP0500958A3 (is)
IL (2) IL156647A0 (is)
IS (1) IS2331B (is)
MX (1) MXPA03006249A (is)
MY (1) MY142762A (is)
NO (1) NO325484B1 (is)
NZ (1) NZ526692A (is)
PL (1) PL367627A1 (is)
RU (1) RU2283838C2 (is)
WO (1) WO2002055510A1 (is)
ZA (1) ZA200305100B (is)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4896387B2 (ja) * 2003-09-30 2012-03-14 武田薬品工業株式会社 チアゾリン誘導体およびその用途
WO2005030740A1 (ja) * 2003-09-30 2005-04-07 Takeda Pharmaceutical Company Limited チアゾリン誘導体およびその用途
EP1926706B1 (en) * 2005-09-13 2012-03-21 Bayer CropScience AG Pesticide bi-phenyl-amidine derivatives
KR100863239B1 (ko) 2007-05-23 2008-10-15 한국과학기술연구원 신규한 2-이미노-1,3-티아졸린계 화합물 및 이를 함유하는ｔ-형 칼슘 채널 저해제
WO2009157415A1 (ja) * 2008-06-23 2009-12-30 東ソー株式会社 蛋白質精製用分離剤及び蛋白質精製方法
KR101049935B1 (ko) 2008-12-03 2011-07-15 한국과학기술연구원 신규한 티아졸린계 화합물 및 이를 포함하는 ｔ-형 칼슘 채널 저해제
ES2351569B8 (es) * 2009-05-07 2012-06-20 Bcn Peptides S.A. Ligandos peptídicos de receptores de somatostatina.
US8710231B2 (en) 2010-08-09 2014-04-29 Pharmadesign, Inc. Inhibitor of casein kinase 1delta and casein kinase 1E
RU2521390C1 (ru) * 2013-03-14 2014-06-27 Общество с ограниченной ответственностью "Тиацен" Производное роданина и средство для профилактики опухолевых заболеваний
EP3498717B1 (en) 2016-08-12 2022-05-04 The Catholic University of Korea Industry-Academic Cooperation Foundation Composition for hardening soft tissue

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1347371A (fr) * 1962-01-19 1963-12-27 Ciba Geigy Agents de lutte contre les organismes nuisibles, renfermant des thiazolines, à usages agricoles et industriels
DE2926771A1 (de) * 1979-07-03 1981-01-15 Hoechst Ag Thiazolidinderivate und verfahren zu ihrer herstellung
DE3049460A1 (de) * 1980-12-30 1982-07-29 Hoechst Ag, 6000 Frankfurt "thiazolinderivate, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen
FR2735777B1 (fr) * 1995-06-21 1997-09-12 Sanofi Sa Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
FR2796643B1 (fr) * 1999-07-22 2005-04-29 Sod Conseils Rech Applic Derives de 2-arylimino-2, 3-dihydrothiazoles, leurs procedes de preparation et leur utilisation therapeutique

Also Published As

Publication number Publication date
FR2819508B1 (fr) 2005-01-21
CN100534988C (zh) 2009-09-02
KR20040038905A (ko) 2004-05-08
ES2248514T3 (es) 2006-03-16
CA2434203C (fr) 2010-12-07
US7220765B2 (en) 2007-05-22
DE60205717D1 (de) 2005-09-29
HUP0500958A2 (en) 2006-01-30
DK1353912T3 (da) 2006-01-09
NO20033120D0 (no) 2003-07-08
MY142762A (en) 2010-12-31
AR035730A1 (es) 2004-07-07
RU2003124749A (ru) 2005-01-10
CN1871224A (zh) 2006-11-29
US20070043095A1 (en) 2007-02-22
KR100874298B1 (ko) 2008-12-18
PL367627A1 (en) 2005-03-07
HUP0500958A3 (en) 2009-12-28
DE60205717T2 (de) 2006-06-22
WO2002055510A1 (fr) 2002-07-18
BR0206407A (pt) 2004-01-06
MXPA03006249A (es) 2003-09-22
NO20033120L (no) 2003-09-11
CZ20031917A3 (cs) 2004-05-12
AU2002233407B2 (en) 2006-11-23
ATE302765T1 (de) 2005-09-15
NO325484B1 (no) 2008-05-13
IL156647A (en) 2009-07-20
FR2819508A1 (fr) 2002-07-19
EP1353912A1 (fr) 2003-10-22
CA2434203A1 (fr) 2002-07-18
ZA200305100B (en) 2004-08-27
EP1353912B1 (fr) 2005-08-24
IL156647A0 (en) 2004-01-04
NZ526692A (en) 2006-04-28
JP2004530643A (ja) 2004-10-07
IS6870A (is) 2003-07-09
JP4452443B2 (ja) 2010-04-21
RU2283838C2 (ru) 2006-09-20

Similar Documents

Publication Publication Date Title
IS7079A (is) Fenýlsúlfónýl-1,3-díhýdró-2H-indól-2-ón afleiður,framleiðsla þeirra og notkun í meðferðarskyni
IS7188A (is) Asabísýklísk-setin samtengd heteróarýl efnasambönd, aðferð til framleiðslu þeirra og notkun
DK1537096T3 (da) Derivater af dioxan-2-alkylcarbamater, fremstilling og terapeutisk anvendelse heraf
IS6661A (is) Bensimídasólafleiður, framleiðsla þeirra og meðferðarleg notkun
DK1417175T3 (da) Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf
DK1539224T3 (da) Antimikrobielt præparat og fremgangsmåde til anvendelse
DK1161434T3 (da) Pyridopyranoazepinderivater, deres fremstilling og terapeutiske anvendelse
DK1513835T3 (da) Piperazinylacylpiperidinderivater, fremstilling og terapeutisk anvendelse heraf
DK1590321T3 (da) Arylalkylcarbamat-derivater, fremstilling og terapeutisk anvendelse deraf
DK1417189T3 (da) Acylaminothiazolderivater, fremstilling og terapeutisk anvendelse heraf
NO20033854D0 (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
DK1525193T3 (da) Acylaminothiazolderivater, deres fremstilling og deres terapeutiske anvendelse
NO20003773D0 (no) Syklobutenderivater, deres fremstilling og deres terapeutiske anvendelser
DK1556382T3 (da) 3-Phenylpyridoindolderivater, fremstilling og terapeutisk anvendelse deraf
DK1387838T3 (da) Cyanoanthranylamid-derivater og deres anvendelse som lægemidler
NO20033506D0 (no) Parasittdrepende preparater og fremgangsmåter for anvendelse
IS2487B (is) Asýloxýpýrrólidín afleiður, framleiðsla og meðferðarnotkun þar á
IS2331B (is) 2-arýlimínó-2,3-díhýdróþíasólafleiður, aðferðir til að framleiða þær og meðferðarfræðileg notkun þeirra
NO20034172D0 (no) Bisykliske guanidinderivater og terapeutiske anvendelser derav
DK1406895T3 (da) Lactonformuleringer og fremgangsmåde til anvendelse deraf
DK1458721T3 (da) 3-heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b]indol-1-carbox-amidderivater, deres fremstilling og terapeutisk anvendelse
NO20033965D0 (no) Caloporosidderivater, fremgangsmåte for deres fremstilling og deres anvendelse
DK1259523T3 (da) Pluraflaviner og derivater deraf, fremgangsmåde til fremstilling og anvendelse deraf
DK1404663T3 (da) Eurotinoner og derivater deraf, fremgangsmåde til deres fremstilling og anvendelse heraf
NO20022482D0 (no) 2-arylkinolinderivater, fremgangsmåte og terapeutisk anvendelse derav